Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)

X-linked Severe Combined Immunodeficiency Clinical Trial

Official title:
Gene Therapy for SCID-X1 Using a Self-inactivating (SIN) Gammaretroviral Vector

Status Active, not recruiting

Clinical Trial Summary

X-linked severe combined immunodeficiency (SCID-X1) is an inherited disorder that results in failure of development of the immune system in boys. This trial aims to treat SCID-X1 patients using gene therapy to replace the defective gene.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Immunologic Deficiency Syndromes
Severe Combined Immunodeficiency
X-Linked Combined Immunodeficiency Diseases
X-linked Severe Combined Immunodeficiency

Clinical Trial Details

NCT number	NCT01175239
Study type	Interventional
Source	Great Ormond Street Hospital for Children NHS Foundation Trust
Contact
Status	Active, not recruiting
Phase	N/A
Start date	April 2011
Completion date	December 2018

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01410019` - Gene Therapy for X-linked Severe Combined Immunodeficiency	Phase 1/Phase 2
	Completed	`NCT00008450` - Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant	Phase 1